U.S. Markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.5418%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.4601%)
     
  • BTC-USD

    61,025.51
    -226.79 (-0.37%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Sientra Reports Second Quarter 2020 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·14 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Continued Strength in Core Breast Products Business Despite COVID-19 Headwinds

Demonstrated Results Through “Drive the Recovery” Practice Initiatives

High-Margin miraDry bioTip® Consumable Model Implemented

SANTA BARBARA, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced its financial results for the second quarter ended June 30, 2020.

Jeff Nugent, Sientra’s Chairman and Chief Executive Officer, said, “While the COVID-19 pandemic has posed unprecedented challenges, we are encouraged by our performance through this stage of the recovery and our competitive position as we exited Q2. We are particularly encouraged by the durability of the demand for our OPUS® breast implants and tissue expanders, as well as the effectiveness of our Drive the Recovery initiatives as we continued to take share from our competitors through new account additions and further penetration of our existing customers. We also successfully transitioned our miraDry business to focus on high-margin, recurring bioTip sales and have seen utilization rates return to pre-COVID-19 levels in key geographic markets, including the United States, as we exited Q2.”

Mr. Nugent concluded, “Overall, these results exceeded our initial expectations and confirmed our confidence in the strength of our business segments. While uncertainty around the future of the recovery persists, we are confident in our ability to emerge from these uncertain times in a position of strength and remain steadfast in building on our core advantages by filling an important real-time need among our customers to help them rebuild their practices stronger than ever.”

Second Quarter 2020 Financial Results

  • Total net sales for the second quarter 2020 were $12.4 million, a decrease of 39% compared to total net sales of $20.5 million for the same period in 2019.

  • Net sales for the Breast Products segment totaled $9.3 million in the second quarter 2020, a decrease of 17% compared to $11.2 million for the same period in 2019.

  • Net sales for the miraDry segment totaled $3.1 million in the second quarter 2020, a 66% decrease compared to $9.3 million for the same period in 2019.

  • Gross profit for the second quarter 2020 was $6.9 million, or 55.4% of sales, compared to gross profit of $12.7 million, or 61.9% of sales, for the same period in 2019.

  • Excluding non cash impairment charges and restructuring charges, operating expenses for the second quarter 2020 were $18.7 million, compared to $37.0 million for the same period in 2019.

  • Net loss for the second quarter 2020 was ($34.3) million, or ($0.68) per share, compared to a net loss of ($37.7) million, or ($1.10) per share, for the same period in 2019.

  • On a non-GAAP basis, the Company reported an adjusted EBITDA loss of ($9.2) million for the second quarter 2020, compared to a loss of ($20.4) million for the same period in 2019.

  • Net cash and cash equivalents as of June 30, 2020 were $71.8 million, compared to $112.1 million as of March 31, 2020.

Key 2020 Business Highlights

  • Filed a PMA Supplement for a line extension to the Company’s portfolio of Sientra OPUS Gel Implants to include larger sizes up to 850 cc.

  • Filed a 510(k) for a next generation Allox2® Tissue Expander.

  • Filed a 510(k) for the Sientra OPUS Gel Sizer to supplement the OPUS Saline Sizer line of products.

  • Re-launched the Sientra.com website to provide a refreshed, up-to-date platform for both augmentation and reconstruction procedures and generate new patients for our plastic surgeons’ practices.

2020 Financial Outlook

  • As previously announced, Sientra is not providing annual guidance for 2020 due to the uncertain scope and duration of the COVID-19 pandemic, and unknown timing of global recovery and economic normalization.

  • To maintain financial health in response to the COVID-19 pandemic and in conjunction with the Company’s previously announced organization efficiency initiatives, management took a number of steps over the previous quarters to simplify operations and reduce spending while ensuring that resources are prioritized on physician and patient-facing activities for the core Breast Product segment. Based on current market conditions the Company is forecasting 2020 annual operating expenses of approximately $105 million to $110 million, excluding impairment and restructuring charges compared to $140 million in 2019, excluding impairment and restructuring charges.

Conference Call

Sientra will hold a conference call today, August 10, 2020 at 4:30 pm ET to discuss second quarter results. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 1379352. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

Sientra has supplemented its US GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP Adjusted EBITDA to GAAP net income (loss), the most directly comparable GAAP measure, is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with Sientra’s financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

(*) Data on file

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on the Company and its operations, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, profitability, outlook and overall business strategy. Such statements are subject to risks and uncertainties, including the scope and duration of the COVID-19 pandemic, the Company’s ability to recapture delayed procedures resulting from the COVID-19 pandemic, the positive reaction from plastic surgeons and their patients to Sientra’s Breast Products, the ability to meet consumer demand, the acceptance and growth of its miraDry segment, and the Company’s ability to manage its operating expenses and cash balance. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Contact
Investor Relations
805-679-8885


Sientra, Inc

Consolidated Statements of Operations

(In thousands, except per share and share amounts)

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

2020

2019

2020

2019

Net sales

$

12,448

$

20,525

$

29,380

$

38,077

Cost of goods sold

5,550

7,813

12,342

14,287

Gross profit

6,898

12,712

17,038

23,790

Operating expenses:

Sales and marketing

7,979

21,918

24,742

42,319

Research and development

2,779

3,270

5,687

6,325

General and administrative

7,958

11,814

17,262

25,289

Restructuring

496

2,235

Impairment

12,674

6,432

12,674

Total operating expenses

19,212

49,676

56,358

86,607

Loss from operations

(12,314

)

(36,964

)

(39,320

)

(62,817

)

Other income (expense), net:

Interest income

18

269

198

573

Interest expense

(3,607

)

(982

)

(5,230

)

(1,932

)

Change in fair value of derivative liability

(18,380

)

(18,510

)

Other income (expense), net

6

23

(27

)

38

Total other income (expense), net

(21,963

)

(690

)

(23,569

)

(1,321

)

Loss before income taxes

(34,277

)

(37,654

)

(62,889

)

(64,138

)

Income tax

Net loss

$

(34,277

)

$

(37,654

)

$

(62,889

)

$

(64,138

)

Basic and diluted net loss per share attributable to common stockholders

$

(0.68

)

$

(1.10

)

$

(1.26

)

$

(2.02

)

Weighted average outstanding common shares used for net loss per share attributable to common stockholders:

Basic and diluted

50,145,538

34,290,073

50,031,105

31,709,067


Sientra, Inc

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

June 30,

December 31,

2020

2019

Assets

Current assets:

Cash and cash equivalents

$

71,799

$

87,608

Accounts receivable, net

24,435

27,548

Inventories, net

45,831

39,612

Prepaid expenses and other current assets

2,498

2,489

Total current assets

144,563

157,257

Property and equipment, net

12,617

12,314

Goodwill

9,202

9,202

Other intangible assets, net

10,051

17,390

Other assets

8,743

8,241

Total assets

$

185,176

$

204,404

Liabilities and Stockholders’ Equity

Current liabilities:

Current portion of long-term debt

$

$

6,508

Accounts payable

3,808

9,352

Accrued and other current liabilities

23,401

32,551

Customer deposits

16,000

13,943

Sales return liability

7,518

8,116

Total current liabilities

50,727

70,470

Long-term debt, net of current portion

63,339

38,248

Derivative liability

34,610

Deferred and contingent consideration

5,228

5,177

Warranty reserve and other long-term liabilities

9,183

8,627

Total liabilities

163,087

122,522

Stockholders’ equity:

Total stockholders’ equity

22,089

81,882

Total liabilities and stockholders’ equity

$

185,176

$

204,404


Sientra, Inc

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Six Months Ended June 30,

2020

2019

Cash flows from operating activities:

Net loss

$

(62,889

)

$

(64,138

)

Adjustments to reconcile net loss to net cash used in operating activities:

Impairment

6,432

12,674

Depreciation and amortization

1,680

1,725

Provision for doubtful accounts

1,257

845

Provision for warranties

363

674

Provision for inventory

1,631

790

Fair value adjustments to derivative liability

18,510

Fair value adjustments of other liabilities held at fair value

(22

)

179

Stock-based compensation expense

3,891

6,611

Payments of contingent consideration liability in excess of acquisition-date fair value

(630

)

Other non-cash adjustments

2,645

128

Changes in assets and liabilities:

Accounts receivable

1,856

(2,206

)

Inventories

(8,026

)

(6,445

)

Prepaid expenses, other current assets and other assets

104

921

Accounts payable, accrueds, and other liabilities

(15,491

)

(1,963

)

Customer deposits

2,057

1,643

Sales return liability

(597

)

972

Legal settlement payable

(410

)

Net cash used in operating activities

(46,599

)

(48,630

)

Cash flows from investing activities:

Purchase of property and equipment

(2,195

)

(2,056

)

Net cash used in investing activities

(2,195

)

(2,056

)

Cash flows from financing activities:

Proceeds from option exercises and employee stock purchase plan

529

789

Net proceeds from issuance of common stock

264

108,028

Tax payments related to shares withheld for vested restricted stock units (RSUs)

(1,428

)

(2,825

)

Repayments under the Term Loan

(25,000

)

Gross borrowings under the PPP loan

6,652

Gross borrowings under the Revolving Loan

8,436

Repayment of the Revolving Loan

(6,508

)

(4,183

)

Net proceeds from issuance of the Convertible Note

60,000

Payments of contingent consideration up to acquisition-date fair value

(370

)

Deferred financing costs

(1,524

)

Net cash provided by financing activities

32,985

109,875

Net increase in cash, cash equivalents and restricted cash

(15,809

)

59,189

Cash, cash equivalents and restricted cash at:

Beginning of period

87,951

87,242

End of period

$

72,142

$

146,431

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets

Cash and cash equivalents

$

71,799

$

146,088

Restricted cash included in other assets

343

343

Total cash, cash equivalents and restricted cash

$

72,142

$

146,431


Sientra, Inc.

Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

Dollars, in thousands

2020

2019

2020

2019

Net loss, as reported

$

(34,277

)

$

(37,654

)

$

(62,889

)

$

(64,138

)

Adjustments to net loss:

Interest (income) expense and other, net

3,583

690

5,059

1,321

Depreciation and amortization

881

894

1,680

1,725

Fair value adjustments to contingent consideration

16

104

16

289

Fair value adjustments to derivative liability

18,380

18,510

Stock-based compensation

1,758

2,911

3,891

6,611

Restructuring

496

2,235

Impairment

12,674

6,432

12,674

Total adjustments to net loss

25,114

17,273

37,823

22,620

Adjusted EBITDA

$

(9,163

)

$

(20,381

)

$

(25,066

)

$

(41,518

)

Three Months Ended

Six Months Ended

June 30,

June 30,

As a Percentage of Revenue**

2020

2019

2020

2019

Net loss, as reported

(275.4

%)

(183.5

%)

(214.1

%)

(168.4

%)

Adjustments to net loss:

Interest (income) expense and other, net

28.8

%

3.4

%

17.2

%

3.5

%

Depreciation and amortization

7.1

%

4.4

%

5.7

%

4.5

%

Fair value adjustments to contingent consideration

0.1

%

0.5

%

0.1

%

0.8

%

Fair value adjustments to derivative liability

147.7

%

0.0

%

63.0

%

0.0

%

Stock-based compensation

14.1

%

14.2

%

13.2

%

17.4

%

Restructuring

4.0

%

0.0

%

7.6

%

0.0

%

Impairment

0.0

%

61.7

%

21.9

%

33.3

%

Total adjustments to net loss

201.8

%

84.2

%

128.7

%

59.4

%

Adjusted EBITDA

(73.6

%)

(99.3

%)

(85.3

%)

(109.0

%)

** Adjustments may not add to the total figure due to rounding